Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression

Deciphering the crosstalk between metabolic reprogramming and epigenetic regulation is a promising strategy for cancer therapy. In this study, we discovered that the gluconeogenic enzyme PCK1 fueled the generation of S-adenosylmethionine (SAM) through the serine synthesis pathway. The methyltransfer...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 133; no. 13
Main Authors Gou, Dongmei, Liu, Rui, Shan, Xiaoqun, Deng, Haijun, Chen, Chang, Xiang, Jin, Liu, Yi, Gao, Qingzhu, Li, Zhi, Huang, Ailong, Wang, Kai, Tang, Ni
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 03.07.2023
Subjects
Development and progression
Genetic aspects
Gluconeogenesis
Health aspects
Hepatoma
Metabolism
Oncology
Phosphoenolpyruvate carboxykinase
Physiological aspects
S-adenosylmethionine
China
Liver cancer
Oncology
Metabolism
Gluconeogenesis
Online AccessGet full text

Cover

More Information
Summary:Deciphering the crosstalk between metabolic reprogramming and epigenetic regulation is a promising strategy for cancer therapy. In this study, we discovered that the gluconeogenic enzyme PCK1 fueled the generation of S-adenosylmethionine (SAM) through the serine synthesis pathway. The methyltransferase SUV39H1 catalyzed SAM, which served as a methyl donor to support H3K9me3 modification, leading to the suppression of the oncogene S100A11. Mechanistically, PCK1 deficiency-induced oncogenic activation of S100A11 was due to its interaction with AKT1, which upregulated PI3K/AKT signaling. Intriguingly, the progression of hepatocellular carcinoma (HCC) driven by PCK1 deficiency was suppressed by SAM supplement or S100A11 KO in vivo and in vitro. These findings reveal the availability of the key metabolite SAM as a bridge connecting the gluconeogenic enzyme PCK1 and H3K9 trimethylation in attenuating HCC progression, thus suggesting a potential therapeutic strategy against HCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Authorship note: DG, RL, XS, HD, and CC contributed equally to this work.
ISSN:1558-8238
0021-9738
1558-8238
DOI:10.1172/JCI161713